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Abstract
Introduction
Obesity is associated with inflammation, which contributes to several obesity-related
comorbidities. This inflammation is characterized by increased inflammatory cytokine
expression in adipose tissue (AT) depots and the liver. Dietary restriction of the essential
amino acid methionine, in rodents, has been shown to improve body weight and
adiposity, decrease high-fat diet- and age-induced inflammation, reduce hepatic steatosis,
and increase insulin sensitivity despite inducing hyperphagia. Recent studies indicate that
dietary methionine restriction (MR) rapidly and persistently increases tissue and
circulating concentrations of the hormone fibroblast growth factor 21 (FGF21). In
rodents, FGF21 has been shown to reduce body weight, increase insulin sensitivity, and
recent reports indicate it may also decrease inflammation. STAT3 is a generally proinflammatory transcription factor which microarray analyses have identified as a
potential “master regulator” of inflammatory processes in MR. We hypothesized that MR
decreases inflammation by increasing FGF21 and downregulating STAT3 signaling.
Methods
24 wild type (WT) C57BL/6J and 24 Fgf21 knock-out (KO) mice were fed a high-fat diet
for four weeks, then randomized to a high-fat control (CON) diet or high-fat MR diet for
13 weeks. RT-PCR was used to measure markers of inflammation in the liver and
epididymal white adipose tissue (EWAT). Western blot analyses were conducted to
determine whether STAT3 activity was affected by MR.
Results

Fgf21KO mice had elevated hepatic expression of Ccl2 (MCP-1), and MR significantly
decreased its expression in Fgf21KO, but not WT mice. In EWAT, Fgf21KO mice had
elevated expression of Emr1 (F4/80), and MR reduced its expression in Fgf21KO mice,
but not WT mice. MR reduced Ccl2 expression in EWAT of both genotypes. Expression
levels of Itgam (CD11b) and IL-6 in EWAT did not differ amongst groups. MR decreased
STAT3 phosphorylation at Tyr705 in both genotypes, but had no effect on Ser727
phosphorylation.
Conclusion
The RT-PCR results suggest that mice lacking FGF21 may be more susceptible to HFDinduced inflammation. Since MR induced comparable reductions in inflammatory
markers in both genotypes, at first glance it appears that FGF21 does not play a role in
the mechanism by which MR decreases inflammation. However, it should be noted that
in Fgf21KO mice, MR induced an unexpected decrease in food intake that resulted in
reduced body weight and adiposity compared to control-fed Fgf21KO mice. Western blot
results support the hypothesis that MR decreases inflammation by downregulating
STAT3 signaling.
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Chapter I
Introduction
The prevalence of obesity is on the rise in the US and is contributing to increased
healthcare costs and the declining health of those with obesity. Obesity is associated with
inflammation, which contributes to several obesity-related comorbidities. This
inflammation is characterized by increased inflammatory cytokine expression in adipose
tissue (AT) depots and the liver. Inflammatory markers often upregulated by obesity
include MCP-1, IL-1β, TNF-α, IFN-γ, F4/80, ITGAM, and ITGAX.
Given the increasing prevalence of obesity, a common goal of researchers is to
identify effective and safe methods for preventing or reversing obesity and metabolic
disease. Dietary restriction of the essential amino acid, methionine, presents as an
intriguing treatment for obesity and its comorbidities. Methionine restriction (MR) has
been shown to improve several signs of metabolic health in rodents. MR reduces body
weight and adiposity, decreases high-fat diet- and age-induced inflammation, reduces
hepatic steatosis, and increases insulin sensitivity. All of these beneficial effects of MR
occur despite an increase in energy intake.
Recent studies indicate that dietary MR rapidly and persistently increases tissue
and circulating concentrations of the hormone fibroblast growth factor 21 (FGF21).
FGF21 increases insulin sensitivity, reduces body weight, and has been shown to
downregulate markers of inflammation in white adipose tissue (WAT) of obese mice and
spleen of arthritic mice. This hormone is considered anti-obesogenic, however serum
levels are increased in obesity, suggesting an FGF21-resistant state. Little is known about
the role of FGF21 in inflammation, though recent studies show that treatment with the
1

inflammatory cytokine TNF-α reduces FGF21 signaling in adipocytes. Additionally,
FGF21 was shown to reduce inflammatory cytokine expression in WAT of obese mice
and in the spleen of arthritic mice.
STAT3, a generally pro-inflammatory transcription factor, is activated by JAKmediated phosphorylation, which allows it to translocate to the nucleus and affect
transcription, propagating the inflammatory response. Microarray analyses suggested that
STAT3 signaling is downregulated by MR in liver and WAT, identifying STAT3 as a
potential mediator of the anti-inflammatory effects of MR.
The purpose of the current study was to determine whether FGF21 mediates the
anti-inflammatory effects of MR and to identify whether downregulation of STAT3
signaling is involved. Gene expression of inflammatory markers and phosphorylation of
STAT3 was measured in AT and liver samples from wild-type (WT) and Fgf21 knockout
(KO) mice.
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Chapter II
Literature Review
Obesity-Induced Inflammation
Obesity is associated with chronic, low-grade, systemic inflammation.1 Obesityinduced inflammation is similar to aging-related inflammation.2 Both aging-related
inflammation and obesity-associated inflammation are characterized by increased
inflammatory cytokine expression and production of reactive oxygen species (ROS).2,3
The inflammatory cytokines produced by obesity are found in circulation, characterizing
the chronic inflammation as “systemic,” and the inflammation is not associated with
infection, characterizing it as “low-grade”.1 Though systemic, the inflammation is
especially increased in adipose and liver tissues.4 Cytokines produced in the AT as a
result of obesity include IL-1β, IL-6, and TNF-α, which are thought to be regulated by
the transcription factor NF-κB.5-9
Macrophages, cells involved in the body’s immune responses, also play an
important role in obesity-induced inflammation.10 Polarization of macrophages influences
their functions, with M1 polarization leading to phagocytosis of dead adipocytes and M2
polarization producing anti-inflammatory cytokines.11,12 Obesity induces polarization
toward the M1 (inflammatory) type, further contributing to an increase in production of
pro-inflammatory cytokines.10 Similarly to adipose tissue, the liver also experiences
increased inflammation in the presence of obesity.4 Kupffer cells, immune cells similar to
macrophages but specific to the liver, will release cytokines, aiding in the development of
inflammation.4,13
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A high fat diet (HFD) is traditionally used to induce obesity and related
inflammation in rodents.14 In a study where a HFD and a normal fat diet (NFD) were fed,
for 12 weeks, to mice and compared, the HFD-fed mice weighed more than the NFD-fed
mice, despite similar calorie consumption.14 The HFD also triggered inflammation,
shown by increases in white adipose tissue (WAT) expression of F4/80, Cd11b, Cd11c,
MCP-1, and TNF-α.14

Obesity-Related Comorbidities
Obesity can lead to a slew of health problems, including type 2 diabetes mellitus
(T2DM), hypertension (HTN), dyslipidemia, hepatic steatosis, and cardiovascular disease
(CVD).1 Inflammation has been linked to the development and progression of insulin
resistance, which can result in the development of T2DM.1,15 Due to the increased
prevalence of obesity, it is especially important to find safe and effective ways to combat
excess adiposity, inflammation, and the comorbidities associated with obesity.
Obesity often leads to the development of T2DM, especially in those genetically
prone to the disease. Obesity increases insulin resistance via inflammation. Specifically,
pro-inflammatory cytokine release (TNF-α, IL-6 and MCP-1), amongst other proinflammatory factors from macrophages and AT, likely contribute to insulin resistance.1618

Insulin resistance causes increased production of insulin by pancreatic β cells. Insulin

resistance leads to the development of T2DM when pancreatic β cells can no longer meet
insulin production needs.16,19,20
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CVD is linked to both systemic inflammation and obesity, independently.21-23 As
discussed previously, obesity leads to systemic inflammation. It is believed that this
systemic inflammation is a risk factor for CVD.21 Systemic inflammation likely causes or
contributes to atherosclerosis.21 Atherosclerosis causes arteries to narrow, which can
contribute to development of HTN. Obesity can cause CVD through the development of
atherosclerosis. Additionally, dyslipidemia, insulin resistance, and T2DM – all associated
with obesity – can contribute to CVD.21,24

Dietary Methionine Restriction
In 1935 a group of scientists demonstrated that calorie restriction (CR) to 60% ad
libitum intake could increase life span in rats.25 In addition, this new dietary approach
resulted in smaller sizes and body weights in the rats.25 Though this research is over 80
years old, it is still relevant today. More recent studies have shown that CR produces lifespan extension effects (30-40%) in multiple species.2,26 However, it is not thought to be
ideal for human applications because of the difficulty in adhering to such a restrictive
diet.2 In hopes of finding a diet that would work for humans and produce similar effects
as CR, researchers searched for components of CR that lead to the enhanced longevity
and decreased body mass benefits. While restriction of carbohydrates and fats did not
seem to produce similar effects to CR, protein restriction did cause life-span extension,
though not to the same degree as CR. Therefore, research continued into the restriction of
various amino acids. In 1993, the restriction of the essential amino acid methionine was
found to produce health benefits similar to those of CR in rats. It was discovered that an
80% reduction of methionine (by weight) in the diet resulted in 30% longer life span and
5

smaller body size and weight in rats.27 Additionally, it appeared as though this diet may
be more feasible for human application because, when fed ad libitum, energy intake
actually increased in methionine-restricted animals.27
Since 1993, more benefits of dietary methionine restriction (MR) have been
uncovered. Reduction in adiposity, especially in the visceral adipose tissue (VAT) depot,
caused by MR has been seen in multiple studies,27-30 which is likely a major contributor
to lowered risk of developing obesity-associated co-morbidities. In fact, surgical removal
of VAT in rats has been shown to increase insulin sensitivity,31 delay diabetes onset,32
and increase mean and maximal life span33 despite similar amounts of total fat when
compared to control groups whom had not had VAT surgically removed.33 MR also
increases insulin sensitivity.28,30,34 Decreased pro-inflammatory marker expression in
peripheral tissues as a result of MR15 could be an effect of decreased adiposity and a
cause of increased insulin sensitivity.
MR reduces hepatic lipid stores, reducing the risk of hepatic steatosis often seen
with obesity,28,35 and reduces serum lipid levels.29 The reduction in hepatic lipid stores
are due to changes in lipid metabolism. In a study on male F344 rats, MR caused an
increase in hepatic fatty acid oxidation and a simultaneous decrease in hepatic fatty acid
synthesis.28
The anti-obesogenic hormone, fibroblast growth factor-21 (FGF21), is increased
by MR.28,36-38 FGF21 has been shown to increase glucose uptake by adipocytes,
independent of insulin activity, prevent obesity, and decrease blood glucose and
triglyceride levels.39
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What makes MR an especially unique dietary approach is its ability to increase
energy expenditure (EE)27,28,35,37 and induce a hyperphagic response.28,29,37 Additionally,
enhanced metabolic flexibility, shown by increased ranges in respiratory exchange ratio
(RER), has been observed in rats.28,37
Plaisance et al. conducted a human study to investigate the effects of MR,
implemented for 16 weeks, in adults with metabolic syndrome.35 All participants
consumed methionine-restricted shakes, unlimited fruits and vegetables (which contain
very little methionine), and some grains (which also do not contain a lot of methionine)
for the entire study. During that time, the control group received methionine supplements
and the MR group received placebo capsules. At the conclusion of the study, the control
and MR groups had comparable reductions in body weight, which caused improved
biomarkers (fasting insulin, plasma adiponectin, plasma TG, FFA, total cholesterol, etc.)
in participants from both groups. That the control group and the MR group both lost
weight could be viewed as a weakness of the study, since it made it difficult to
distinguish the effects of dietary MR. Two effects were unique to MR: 1) subjects fed the
MR diet had significantly less lipid storage compared to the control group, and 2)
subjects in the MR group oxidized more fat, as indicated by lower RQ values. Despite
some promising results, the study design contained a major flaw. While methionine was
restricted, the shakes contained cysteine, a metabolic product of methionine, which
caused diminished efficacy of the restriction of methionine in the shakes. Studies have
shown that when cysteine is added back to the MR diet, many of the beneficial effects of
MR are reversed.40 Cysteine addition to the MR diet in rodents ameliorated the ability of
MR to decrease body weight, adiposity, and serum triglycerides.40 Future clinical studies
7

must eliminate cysteine in addition to restricting methionine in order to collect nonconfounded results.35
The multitude of benefits provided by this diet, in addition to the fact that it does
not restrict food portions or calories, makes it a contender for human applications,
specifically in populations suffering from metabolic syndrome and other obesityassociated morbidities. Additionally, further investigation into the mechanisms mediating
the beneficial effects of MR could yield potential therapeutic strategies to treat obesity
and related complications.

Anti-Inflammatory Effects of MR
MR induces anti-inflammatory actions in both liver and WAT.15 These antiinflammatory effects seem to not be a direct effect of decreased adiposity but, rather,
from metabolic changes.15 Using quantitative RT-PCR to measure expression of proinflammatory genes, Wanders et al. described transcriptional anti-inflammatory effects of
MR in rats fed either MR or a control diet for 20 months. In retroperitoneal white adipose
tissue (RPWAT), expression levels of Ccl2 (MCP-1), Il1b, Tnf, Ifng, Emr1 (F4/80),
Itgam, and Itgax were decreased in rats fed the MR diet. In inguinal white adipose tissue
(IWAT) MR reduced Ccl2 (MCP1) expression by 2.9-fold. Epidydimal white adipose
tissue (EWAT) analysis showed downregulation of Emr1, Itgam,and Itgax mRNA
expression. Finally, hepatic expression of Ccl2, Il1b, Tnf, Ifng, Emr1, Itgam, and Itgax
were reduced by MR. In addition to MR, a CR diet was assessed in the same study.
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Results indicated that MR caused greater downregulation of inflammatory genes than CR
in both liver and AT.15

Fibroblast Growth Factor 21 (FGF21)
FGF21 is a hormone secreted primarily by the liver, but also by AT.41,42 In these
organs, it works to regulate glucose and lipid metabolism and homeostasis.41-44 Through
PPARα-mediated activation, FGF21 binds to an FGF receptor with help from co-receptor
βKlotho. Binding to the FGF receptor causes it to dimerize, autophosphorylate, and
activate a signaling cascade. The signaling cascade causes the activation of extracellular
mitogen-activated protein kinase 1 & 2 (ERK1/2), which allows it to activate several
transcription factors.43 FGF21 regulates glucose metabolism potentially through this
mechanism. By upregulating GLUT1 expression in AT, glucose uptake is increased,
independent of insulin action.42,43,45
Although FGF21 is considered anti-obesogenic, serum levels tend to be elevated
in both obese mice and humans. Many scientists have proposed the idea of “FGF21resistance,” a concept similar to that of insulin-resistance, where the body is desensitized
to the hormone and, therefore, increases its production with little benefit.41-43,45 Scientists
seem to agree that FGF21 resistance is a result, not the cause of obesity.43,45 Despite
resistance to the hormone, exogenous administration of FGF21 to obese rodents has
shown improvements in weight with little to no side effects,44 making administration of
FGF21 a potential pharmacological therapy for obesity.
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In addition to its work in improving glucose and lipid metabolism and
homeostasis, FGF21 is associated with reduced inflammation. Treatment of adipocytes
with TNF-α decreased FGF21 signaling by reducing the expression of its essential coreceptor βKlotho.46 In addition to being affected by inflammation, FGF21 also reduces
inflammation. A study using recombinant FGF21 showed that FGF21 reduced
inflammatory cytokines IL-6 and TNF-α in WAT of rats with monosodium glutamateinduced obesity.47 In arthritic mice, exogenous FGF21 administration caused
downregulation of several pro-inflammatory cytokines in the spleen, including TNF-α,
IL-1β, and IL-6.48,49 Research on the role FGF21 plays in inflammation is limited but
promising, highlighting the importance of further research into the hormone’s antiinflammatory properties.
One option for research into FGF21 is the use of Fgf21 knock-out (Fgf21KO)
mice in comparison to control wild-type (WT) mice. Fisher and colleagues sought to
investigate similarities and differences between Fgf21KO and WT mice to establish that
the two strains are phenotypically similar and comparisons between the two are valid.43
While on chow-fed diets WT mice weighed less than Fgf21KO mice. Once put on a HFD
that was intended to be obesogenic, the WT and Fgf21KO mice took on similar levels of
adiposity. WT mice also experienced better glucose tolerance while on the chow diets,
but these differences disappeared on the HFD. Circulating non-esterified fatty acids were
also no longer different once the mice were put on the HFD. This research gives
validation that WT and Fgf21KO mice can be appropriately compared when on a HFD.43
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Signal Transducer and Activator of Transcription 3 (STAT3)
The STATs are a set of transcription factors that are activated through the
phosphorylation mediated by janus kinases (JAKs) and, once activated, dimerize, move
to the nucleus, and affect gene transcription.30,50 Activators of the JAK-STAT pathway
include cardiotrophin-1 (CT-1),51-53 growth hormone (GH),51,54 interferon gamma (IFNγ),51,55-57 interleukins 6 and 11 (IL-6 and IL-11),55,58,59 leukemia inhibitory factor
(LIF),51,55,57,59,60 neuropoietin (NP),51,61-63 and oncostatin M (OSM).51,55,57,59,64 STAT3 is
widely recognized for its role in propagating inflammation, but has been studied
primarily for its role in cancer-related inflammation. Two phosphorylation sites have
been identified on STAT3: Tyr705 and Ser727.50,65,66 The actions of and differences in
phosphorylation sites are not completely understood. Phosphorylation at Tyr 705 appears
to promote the dimerization of STAT3 and is essential for STAT3 activation,50,66,67 while
phosphorylation at Ser727 seems to enhance the transcription effects of STAT3.50,66
STAT3 is found in adipocytes68,69 and evidence suggests that phosphorylated STAT3
(pSTAT3) plays a role in adipogenesis and preadipocyte differentiation.68,70-73 pSTAT3
also upregulates the expression of pro-inflammatory markers.2,74

MR and STAT3
Microarray analyses conducted on tissue samples from rats fed a control, MR, or
40% calorie-restricted (CR) diet for 20 months showed that both MR and CR decreased
expression of inflammatory genes in liver and WAT of rats.15 In fact, despite similar
reductions in body weight and adiposity between the MR and CR rats, MR had a
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significantly greater anti-inflammatory effect in liver and adipose tissue than CR.
Furthermore, analysis using Ingenuity Pathway Analysis (Qiagen) software identified a
downregulation of STAT3 signaling in liver and WAT of rats fed the MR diet.2 These
data suggest that STAT3 may be the mechanism behind the MR-induced downregulation
of age- and obesity-induced inflammation.
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Chapter III
Methods
Animal Study
Animal studies were conducted at Pennington Biomedical Research Center, and
tissues were generously provided by Dr. Tom Gettys. All animal experiments were
reviewed and approved by the Pennington Institutional Animal Care and Use Committee
using guidelines established by the National Research Council, the Animal Welfare Act,
and the PHS Policy on humane care and use of laboratory animals. Male WT C57BL/6J
mice were obtained from Jackson Labs (Bar Harbor, ME, USA), and Fgf21KO (KO)
mice were kindly provided by Dr. Steve Kliewer (UT Southwestern). 24 WT C57BL/6J
and 24 Fgf21KO mice, age 12 weeks, were fed a HFD for four weeks. After those four
weeks, 12 WT and 12 KO mice were placed on high-fat methionine-restricted (MR) diets
while the other mice remained on the control HFD (CON). The CON diet contained .86%
methionine, by weight, and the MR diet contained .17% methionine and no cysteine (an
80% reduction, typical for MR diets in mice). The WT and KO mice were fed the CON
or MR diet for 13 weeks after randomization. After these 13 weeks, mice were
euthanized and tissues were collected and flash frozen in liquid nitrogen.

RNA Extraction and Real-time PCR
RNA was extracted from EWAT and liver samples using the Qiagen RNeasy
Lipid Tissue Mini Kit 50. DNAse digestion was performed to improve purity of RNA.
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RNA concentrations and purity were verified by nanodrop. From isolated RNA, reverse
transcription was performed to make cDNA.
Real-time PCR (RT-PCR) using SYBR-green reagents was performed on Liver
samples to measure expression of the inflammatory marker genes for Ccl2 (MCP-1) and
Emr1 (F4/80) and on EWAT samples to measure expression of the inflammatory marker
genes for Emr1 (F4/80), Itgam (CD11b), Il6 (interleukin-6), and Ccl2 (MCP-1). Gene
expression measures were normalized to cyclophilin.
Gene
Forward Primer
Reverse Primer
Cyclophilin 5’-CTT CGA GCT GTT TGC
5’-AGA TGC CAG GAC CTG
AGA CAA AGT-3’
TAT GCT-3’
Ccl2
5’-GGA GAG ACA GCG GTC
5’-CCA GCC GGC AAC TGT
GTA AG-3’
GA-3’
Emr1
5’-GTG CCA TCA TTG CGG
5’-GAC GGT TGA GCA GAC
GAT TC-3’
AGT GA-3’
Itgam
5’-CCA CAC TAG CAT CAA
5’-CCC TGA TCA CCG TGG
GGG CA-3’
AGA AG-3’
Il6
5’-ATG GAT GCT ACC AAA
5’-TGA AGG ACT CTG GCT
CTG GAT-3’
TTG TCT-3’
Table 1. Forward and reverse primer sequences used in RT-PCR.

Protein Extraction and Immunoblot Analysis
To determine if MR decreases inflammation through downregulation of STAT3
signaling and to determine the role of FGF21 in anti-inflammatory effects of MR,
western blot analyses of STAT3 phosphorylation at Tyr705 and Ser727 were conducted.
Protein extracts from tissues were made by homogenizing ~100mg of each sample in
300uL of radioimmunoprecipitation assay (RIPA) buffer containing protease and
phosphatase inhibitors. Lysates were incubated in lysis buffer on ice for 20 minutes and
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were then centrifuged for 30 minutes at 13,200 RPM at four degrees Celsius. The
infranatant was collected and assayed for protein concentrations. Protein concentrations
were determined by Lowry Protein assay. Protein samples were combined with laemmli
buffer and boiled for five minutes. Protein from each sample were loaded onto a 10%
Criterion Precast (Bio-Rad Laboratories) gel. Proteins were separated via electrophoresis
at 90-110V for 2.5 hours. Proteins (total amounts varied between membranes) were
transferred to a PVDF membrane overnight at 10V. Membranes were rinsed with
deionized water the following day and were incubated in blocking buffer (5% BSA in
TBSt) for 1 hour. Primary antibody (pSTAT3Tyr705 and pSTAT3Ser727 in 5% BSA and
total STAT3 in 1% BSA) was added to a pouch with the membranes and incubated for
either about one hour or overnight (varied by membrane and by antibody) at four degrees
Celsius. Afterward, the membranes were washed in TBSt on a shaker for five minutes,
three times. Secondary antibody was added to the membranes (anti-rabbit, in 1% BSA)
and incubated for one hour, followed by another three washes in TBSt. The membrane
was then covered with ECL for five minutes and immediately imaged using ImageQuant
LAS4000 equipment and software (GE Healthcare). pSTAT3Tyr705 and pSTAT3Tyr705
antibody from Cell Signaling Technology (Danvers, MA) were used; STAT3 antibody
was from Santa Cruz Biotechnology (Santa Cruz, CA). Band densities of pSTAT3 were
quantified using ImageJ software and normalized to total STAT3.

Statistical Analysis
RT-PCR data were analyzed by one-way ANOVA. Tukey’s multiple comparisons
test was used to identify significant differences between groups. Western blot data were
15

analyzed by unpaired t-test. Data was analyzed by Prism software (version 7.00,
GraphPad, La Jolla, California).
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Chapter IV
Results
Liver expression of MCP-1 and F4/80
KOCON mice had significantly increased expression of the inflammatory
chemokine Ccl2 (MCP1) in the liver compared to WT mice (Fig. 1). MR decreased
MCP-1 expression in KO mice (p<0.0001), and tended to do so in WT mice. However,
WT mice fed the Con diet had significantly less MCP-1 expression in their liver
compared to KO mice. Expression of the inflammatory macrophage marker, F4/80
expression was unaffected by diet and genotype (Fig. 2).
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Figure 1. Hepatic Ccl2 (MCP1) mRNA expression in WT and Fgf21KO mice. Values
are means ± SEM, n=7-10.
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Figure 2. Hepatic Emr1 (F4/80) mRNA expression in WT and Fgf21KO mice. Values
are means ± SEM, n=6-9.

MR decreased EWAT MCP-1 expression in both WT and Fgf21KO mice
MR decreased MCP-1 expression in EWAT of WT and Fgf21KO mice. No
significant differences in EWAT MCP-1 mRNA expression were found between
genotypes (Fig. 3).
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Figure 3. EWAT Ccl2 mRNA expression in WT and Fgf21KO mice. Values are means ±
SEM, n=8-10.

MR decreased EWAT F4/80 expression in Fgf21KO mice
Fgf21KO mice had elevated Emr1 (F4/80) expression in EWAT compared to WT
mice, and MR decreased its expression in Fgf21KO mice, but not in WT mice (Fig. 4).
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Figure 4. EWAT Emr1 mRNA expression in WT and Fgf21KO mice. Values are means
± SEM, n=8-10.

EWAT Itgam and Il6 expression did not differ between groups
mRNA expression of Itgam, an inflammatory macrophage marker, in EWAT was
similar between all four groups (Fig. 5). Additionally, mRNA expression of the
inflammatory cytokine Il6 in EWAT was similar between all four groups of mice.
Though trends seen in the figures are similar to those of Ccl2 and Emr1, differences
between groups were not statistically significant (Fig. 6).
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Figure 5. EWAT Itgam mRNA expression in WT and Fgf21KO mice. Values are means
± SEM, n=5-9.
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Figure 6. EWAT IL-6 mRNA expression in WT and Fgf21KO mice. Values are means ±
SEM, n=8-9.
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EWAT pSTAT3Tyr705, but not pSTAT3Ser727, was reduced by MR in WT mice
Since STAT3 is a transcription factor known to propagate inflammation and
microarray analyses identified STAT3 as a potential master regulator of the antiinflammatory effects of MR, STAT3 phosphorylation in EWAT was measured. Western
blot analyses of EWAT indicated that MR significantly decreased phosphorylation of
STAT3 at Tyr705 in WT mice (p=0.0118) (Fig. 7). The analyses also showed no
significant differences in phosphorylation of STAT3 at Ser727 between the two groups
(Fig. 7).

Figure 7. EWAT pSTAT3Tyr705 and pSTAT3Ser727 in WTCON and WTMR mice. Values
are means ± SEM, n=6.
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EWAT pSTAT3Tyr705, but not pSTAT3Ser727, was significantly reduced by MR in Fgf21KO
mice
Similarly to the WT mice, MR decreased phosphorylation of STAT3 at Tyr705 in
the Fgf21KO mice (p=0.009) (Fig. 8). However, phosphorylation of STAT3 at Ser727
was not significantly different between the two groups (Fig. 8).

Figure 8. EWAT pSTAT3Tyr705 and pSTAT3Ser727 in KOCON and KOMR mice. Values
are means ± SEM, n=6.

EWAT pSTAT3Tyr705 was affected by absence of FGF21 while pSTAT3Ser727 was not
WTCON and KOCON were compared to assess the effects that absence of Fgf21
has on STAT3. Western blot analyses indicated that phosphorylation of STAT3 at
Tyr705 was increased in Fgf21KO mice compared to WT mice (p=0.0177) (Fig. 9).
Phosphorylation of STAT3 at Ser727, however, was not significantly different between
WTCON and KOCON (Fig. 9).
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Figure 9. EWAT pSTAT3Tyr705 and pSTAT3Ser727 in WTCON and KOCON mice. Values
are means ± SEM, n=6.
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Chapter V
Discussion
Obesity increases inflammation throughout the body.1 This inflammation is
characterized by increased inflammatory cytokine expression and increased ROS
production, similar to inflammation observed in aging. 2,3 Inflammatory markers often
upregulated in obesity include MCP-1, IL-1β, TNF-α, IL-6, IFN-γ, F4/80, ITGAM, and
ITGAX. 15
NF-κB, a proinflammatory transcription factor, is activated by hypoxia in
adipocytes and AT macrophages. This hypoxia response is initiated by adipocyte
hypertrophy.1,75 Activation of this transcription factor is to blame for the upregulation of
many pro-inflammatory cytokines, including TNF-α, IL-1β, IL-6, and MCP-1.1,14,75 In
addition to NF-κB activation, polarization of macrophages to the M1 type causes
upregulation of pro-inflammatory cytokines.4,10,13
CR has gained attention for its ability to increase lifespan and adiposity in
rodents.25 However, use of this dietary approach is not ideal for humans.2 MR has been
shown to produce similar benefits as CR,27-30 but, interestingly, induces a hyperphagic
response with simultaneous increased energy expenditure.27-29,35,37 MR also increases
insulin sensitivity and decreases pro-inflammatory cytokine expression, reduces hepatic
lipid stores, and reduces serum lipid levels.15,28,29,31,35 In the present study, both WTMR
and KOMR mice weighed less than the CON groups. This reduction in weight was
accompanied by a reduction in adiposity in WTMR and KOMR. Food intake increased in
WTMR mice in comparison to WTCON, however KOMR mice did not develop a
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hyperphagic response in comparison to KOCON (unpublished data from Gettys and
colleagues).
MR has been shown to decrease the pro-inflammatory cytokines MCP-1, IL-1β,
TNF-α, IFN-γ, F4/80, ITGAM, and ITGAX in WAT and liver.15 In the present study,
measures for MCP-1 and F4/80 in the liver and MCP-1, F4/80, ITGAM, and IL-6 in
EWAT were gathered. Our data for MCP-1 were in agreement with other data that
suggests downregulation of the gene in EWAT and liver of mice on dietary MR. EWAT
F4/80, ITGAM, and IL6 were not in agreement with other data, but the data were
trending toward downregulation of these pro-inflammatory genes in MR. A flaw of our
study and similar studies is that only portions of each tissue from each mouse is taken and
used for RNA isolation and subsequent reverse transcription and RT-PCR. Fluctuations
of gene expression in various portions of the same tissue are common. Because we can
only feasibly take a portion of each tissue, gene expression levels may be slightly
different from total tissue gene expression. This may be why we found trends between
groups without significant differences. Additionally, increasing the number of samples
used in the study could help determine significance by limiting the SEM.
FGF21 is a hormone that increases glucose uptake by adipocytes, prevents
obesity, decreases blood glucose, and decreases triglyceride levels.39 Studies show that
MR increases levels of FGF21 in circulation.28,36-38 Inflammation (specifically, the
presence of TNF-α) decreases FGF21 signaling in adipocytes through the reduced
expression in co-receptor βKlotho.46 FGF21 serum levels are higher in obese rodents and
humans, possibly as a result of FGF21 resistance. Exogenous administration, however,
has been shown to improve weight in obese rodents and decrease pro-inflammatory
26

cytokine expression in the spleen of arthritic mice, suggesting its potential use as a
pharmacologic agent.44,48,49 Additionally, recombinant FGF21 reduced expression of proinflammatory cytokines in mouse WAT.47 Our data showed increased expression of Liver
MCP-1 and EWAT F4/80 in KOCON mice when compared to all other groups. This
suggests the Fgf21KO mice were more susceptible to HFD-induced inflammation.
Western blot analyses showed increased phosphorylation of STAT3 at Tyr705 in
KOCON when compared to WTCON. This suggests that the increased inflammation seen
in the absence of FGF21 is potentially mediated by the phosphorylation of STAT3 at
Tyr705.
STAT3, a generally pro-inflammatory transcription factor, is activated at two
phosphorylation sites: Tyr705 and Ser727.50,65,66 Our data indicate that phosphorylation
of STAT3 at Tyr705 is downregulated by MR in both WT and KO mice. Additionally,
phosphorylation of STAT3 at Tyr705 is upregulated in KOCON mice when compared to
WTCON mice. These data suggest that the mechanism by which MR downregulates
phosphorylation of STAT3 at Ser727 is independent of Fgf21. Phosphorylation of
STAT3 at Ser727 was unaffected by both MR and lack of FGF21. However, Tyr705 is
the main site of phosphorylation on STAT3 while Ser727 is the secondary maximal
activation site. The data which show downregulation of phosphorylated STAT3 at
Tyr705 are in agreement with our hypothesis that STAT3 is a potential master regulator
of inflammation in MR.
In conclusion, MR decreased inflammation in both WT and Fgf21KO mice,
indicating that Fgf21 does not play a role in the mechanisms by which MR reduces
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inflammation. Western blot results support the hypothesis that MR decreases
inflammation by downregulation of STAT3 signaling.
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